Press Release: GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression

DUBLIN, Ireland, Jan. 18, 2024 (GLOBE NEWSWIRE) — GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced that it recently received a communication from the European Patent Office (EPO) that it has been granted a patent with claims directed to mebufotenin (5-MeO-DMT) or a pharmaceutically acceptable salt thereof for use in treating patients diagnosed with major depressive disorder (MDD) and treatment-resistant forms of MDD, such as treatment-resistant depression (TRD).

The newly granted patent, EP3927337, which will have an effective date of February 14, 2024, and an expiry date of no earlier than 2040, is expected to cover all mebufotenin (5-MeO-DMT) and mebufotenin salt products for use in the treatment of MDD and TRD, including but not limited to products administered through pulmonary inhalation, intravenous and intranasal routes. It is therefore expected to effectively fortify the company’s position at the forefront of novel rapid-acting antidepressant treatments. Similar patent applications are pending on behalf of the company in the US and in over thirty other jurisdictions, aiming to provide broad coverage in all key geographies for the therapeutic use of mebufotenin (5-MeO-DMT) in MDD and TRD.

The present grant represents the first of many expected milestones for GH Research’s intellectual property (IP) portfolio as the company continues to advance its additional more than 25 unique international patent applications, that relate to various further aspects of mebufotenin (5-MeO-DMT) therapies, including use for treatment of various disorders via inhaled, nasal, buccal, sublingual, intravenous, intramuscular or subcutaneous routes; novel aerosol compositions of matter; novel manufacturing methods for preparation and purification; novel salt forms; and novel delivery device-related features.

Theis Terwey, CEO and Co-founder of GH Research said: “We are committed to providing highly effective new therapies to patients in mental health care who are underserved by existing treatments. Having a strong IP portfolio helps us with this mission, and it is satisfying to have the EPO endorse the strength of our IP. We believe the EPO’s grant of this patent, in view of various third-party observations submitted during the examination process, reflects the fact that our IP portfolio is characterized by early priority dates and is underpinned by the earliest clinical data on the use of mebufotenin to treat mental illness. We feel well placed to progress the rest of our patent portfolio through the examination process in Europe, the US and beyond, and are looking forward to exploring additional opportunities with mebufotenin through continuous research and development.”

About GH Research PLC

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC’s initial focus is on developing its novel and proprietary mebufotenin (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).

GH Research PLC’s annual report on Form 20-F/A filed with the U.S. Securities and Exchange Commission for the year ended December 31, 2022, is available at and shareholders may receive a hard copy free of charge upon request.


Primary Sponsor


Karma Koala Podcast

Top Marijuana Blog